Long-Term Impact of Molecular Epidemiology Shifts of Methicillin-resistant Staphylococcus aureus on Severity and Mortality of Bloodstream Infection

Strain and data collection

Previously,^4,6 we used to collect MRSA strains detected in one or more blood cultures because collecting more than two sets of blood cultures was not a common practice at our hospital. However, collecting two or more sets of blood cultures has become more common since the 2010s. Therefore, in this study, we collected MRSA strains detected in two or more blood cultures between January 2012 and December 2019 at Nagasaki University Hospital using the same inclusion criteria for nationwide surveillance.⁵ Nagasaki University Hospital, a tertiary medical institution with 874 beds, is located in Nagasaki Prefecture, the westernmost part of Japan. We also collected information regarding blood culture collection location (outpatient or inpatient), the day of hospitalization blood culture collection, antimicrobial use during the 30 days before the onset of BSI, initial antimicrobial regimens for BSI, mortality, and the details required to calculate the Charlson comorbidity index⁷ and Sequential Organ Failure Assessment (SOFA) score⁸ from the medical records at Nagasaki University Hospital.

Antimicrobial susceptibility testing

We measured the minimum inhibitory concentrations (MICs) using broth microdilution testing using a dry plate (Eiken, Tokyo, Japan), according to the manufacturer’s instructions. Antimicrobial susceptibility was determined according to the Clinical and Laboratory Standards Institute guidelines (CLSI M100-Ed31) and the European Committee on Antimicrobial Susceptibility Testing Version 11.0.

Whole-genome sequencing (WGS)

All procedures were performed according to the respective manufacturer’s instructions. After extracting the DNA from MRSA strains using a Quick-DNA Fungal/Bacterial Kit (ZYMO RESEARCH, Irvine, CA, United States), we performed WGS on the MRSA strains isolated between 2012 and 2015 using an Ion PGM HiQ View OT2 Kit (Thermo Fisher Scientific, Waltham, MA, USA). Enriched samples were loaded onto an Ion 318 chip and sequenced using an IonTorrent Personal Genome Analyzer with an Ion PGM HiQ View Sequencing Kit (Thermo Fisher Scientific). DNA libraries were generated for Ion PGM using the Ion Xpress Plus Fragment Library Kit (4471269; Thermo Fisher Scientific). We performed WGS for the MRSA strains isolated between 2016 and 2019 using the MiSeq system (Illumina, San Diego, CA, United States) and MiSeq Reagent kit v3 (600 cycles) (Illumina). We also performed WGS for MRSA strains isolated between 2012 and 2015, which needed to be retested using the MiSeq system. We generated DNA libraries for the Miseq system using Invitrogen (Waltham, MA, United States) Collibri ES DNA Library Prep Kit for Illumina (A38607096, ThermoFisher Scientific).

Analysis of molecular characteristics

Sequence data were assembled using the CLC Genomics Workbench Microbial Genomics Module (Qiagen, Venlo, Netherlands). Multilocus sequence type (MLST) was determined using PubMLST (https://pubmlst.org).⁹ We determined the SCCmec and spa types using SCCmecFinder (ver1.2)¹⁰ and spaTyper (software version 1.0 and database version 2023-6-19)¹¹ on the Center for Genomic Epidemiology website (https://www.genomicepidemiology.org), respectively. Resistance and virulence genes were detected using ResFinder (software version 2023-08-22 and database version 2023-04-12) and VirulenceFinder (software version 2.0.3 and database version 2022-12-02)^12,13 on the Center for Genomic Epidemiology website (https://www.genomicepidemiology.org), respectively. Our previous study revealed very similar bacteriological characteristics between ST1-carrying SCCmec type IV (ST1-MRSA-IV) and ST2725-carrying SCCmec type IV (ST2725-MRSA-IV);⁵ further, a preliminary investigation as part of the current study showed that ST1-MRSA-IV, ST2725-MRSA-IV, and ST5213-MRSA- IV had the same characteristics. Hence, we combined the data from ST1-MRSA-IV, ST2725- MRSA-IV, and ST5213-MRSA-IV as CC1-MRSA-IV. Core-genome MLST (cgMLST) was performed using Ridom SeqSphere+ v.9.0.10 (Ridom GmbH, Münster, Germany. A minimum spanning tree (MST) or unweighted pair group method with arithmetic mean (UPGMA) tree was created based on MLST, cgMLST, and S. aureus accessories using Ridom SeqSphere+ (ver. 9). Samples with more than 10% missing values among the data used for the distance calculation were excluded from constructing the MST or UPGMA. For the UPGMA using strains that were detected during the previous nationwide surveillance,⁵ we excluded 13 strains detected at Nagasaki University Hospital to avoid duplication. In UPGMA, a cluster of MRSA strains was classified with a distance of 0.1, and subclusters of ST8 with SCCmec type I (ST8-MRSA-I) and ST8-MRSA-IV, CC1-MRSA-IV, and ST5-MRSA-II were classified with a distance of 0.03.

Data collection from previous studies

Data collected during 2003–2007 and 2008–2011 have been reported previously.^4,6 In this study, we compared the new data with the data from the previous study database to confirm the changes in SCCmec type and patient characteristics. To match the study period of previous studies with that of this study, the SCCmec type data obtained in this study were analyzed separately for four years, 2012–2015 and 2016–2019.

Statistical analysis

All statistical analyses were performed on GraphPad Prism 10 (version 10.1.0; GraphPad Software, Boston, MA, United States of America). Continuous variables were expressed as mean ± standard deviation. Categorical variables were compared using Fisher’s exact test, and q values were calculated using the Benjamini–Hochberg method for multiple comparisons. Continuous variables were compared using Student’s t-test for two-group comparisons and Tukey’s test for multiple comparisons. The statistical significance level was set at p < 0.05 and q < 0.05, and the p-value was considered not significant (n.s.) if it was greater than 0.2.

Ethics

This study was approved by the Ethics Committee of the Nagasaki University Hospital (20072018). MRSA strains collected from blood cultures were anonymized and individually numbered. Patient information collected from the medical records was also anonymized and individually numbered when. The Ethics Committee of Nagasaki University Hospital waived the requirement for informed consent.

Changes in SCCmec type from 2003 to 2019

Twenty-seven and fifty-eight MRSA strains were isolated during 2012–2015 and 2016–2019, respectively. The percentages of SCCmec types I, II, and IV during 2012–2015 were 37.0%, 37.0%, and 25.9%, respectively. The percentages of SCCmec types I, II, IV, and V during 2016– 2019 were 15.5%, 15.5%, 65.5%, and 3.4%, respectively. Fig. 1 and Supplementary Table 1 show the changes in SCCmec type from 2003 to 2019. SCCmec type II was the most frequently detected type from 2003 to 2015. However, its frequency decreased significantly from 79.2% during 2003–2007 to 15.5% during 2016–2019 (q < 0.001). In contrast, the percentage of SCCmec type IV increased dramatically from 18.2% during 2003–2007 to 65.5% during 2016– 2019 (q < 0.001). SCCmec type I showed changes that differed from those of SCCmec types II and IV. The percentage of SCCmec type I cases increased significantly from 2.6% during 2003– 2007 to 37.0% during 2012–2015 (q < 0.001). SCCmec type I was one of the most frequently detected SCCmec types from 2012 to 2015; however, its prevalence decreased by more than 50% (15.5 %) during 2016–2019.

• Download figure
• Open in new tab

Fig. 1. Changes in SCCmec type

Changes in SCCmec type from 2003 to 2019 were evaluated. Data regarding SCCmec type during 2003–2007 and 2008–2011 have been reported previously. The inclusion criteria for MRSA strains in this study (2012–2015 and 2016–2019) differed from those used in previous studies (2003–2007 and 2008–2011). In previous studies, MRSA strains collected from one or more blood cultures were analyzed, whereas in this study, MRSA strains collected from two or more blood cultures were analyzed.

Changes in patient characteristics from 2003 to 2019

Table 1 and Supplementary Table 1 show the characteristics of patients in each study period. There were no significant differences in the patients’ backgrounds, such as age, sex, or underlying diseases, except for the classification of infection; the percentage of healthcare- associated infections was significantly higher during 2012–2015 than during 2008–2011 (3.6% vs. 22.2%, q = 0.020). Further, the sources of MRSA infection changed from 2003 to 2019. The percentage of intravascular device-related BSI increased significantly from 18.1% during 2003– 2007 to 46.6% during 2016–2019 (q = 0.002). In contrast, the percentage of respiratory tract infection-related BSI significantly decreased from 16.9% during 2003–2007 to 20.5% during 2008–2011 and 1.7% during 2016–2019 (q = 0.013 and 0.004, respectively). The severity of BSI also changed between 2003 and 2019. SOFA score significantly decreased from 5.8 ± 0.5 during 2003–2007 to 3.1 ± 0.5 during 2016–2019 (p = 0.004), and accordingly, the in-hospital mortality improved from 39.8% during 2003–2007 to 15.5% during 2016–2019 (q = 0.015).

MRSA types based on ST and SCCmec type during 2012–2019

The predominant combination of ST and SCCmec types during 2012–2019 was ST8-MRSA- IV (37.6%), followed by ST8-MRSA-I (22.4%), ST5-MRSA-II) (18.8%), and CC1-MRSA-IV (9.4%) (Fig. 1A). The changes in the major combinations are shown in Fig. 2B and Supplementary Table 2. Although there was no change in the percentage of ST8 between 2012– 2015 and 2016–2019, the combination of SCCmec type with ST8 differed between the two periods. The percentage of ST8-MRSA-IV was significantly higher during 2016–2019 (44.8%) than during 2012–2015 (22.2%). In contrast, the percentage of ST8-MRSA-I was significantly lower during 2016–2019 (15.5%) than during 2012–2015 (37.0%; p = 0.048).

• Download figure
• Open in new tab

Fig. 2. Major MRSA types based on sequence type and SCCmec type

SCCmec type and sequence type (ST) from 2012 to 2019 were evaluated (A). The changes in the percentage of major MRSA types based on the SCCmec type and ST from 2012 to 2019 was also evaluated (B). We decided on ST based on whole-genome sequencing using the CLC Genomics Workbench and the CLC Microbial Genomics Module (Qiagen, Venlo, Netherlands).

Patient characteristics and drug-resistance rate in the major MRSA types

Table 2 and Supplementary Table 3 show the patient characteristics for each major combination. No significant differences were observed with respect to the patient characteristics among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1- MRSA-IV, with 2.3 ± 0.6 and 12.5%, respectively than those of other major MRSA types; however, there was no statistical difference.

The drug-resistance rates of the major MRSA types to different antimicrobial agents are shown in Table 2 and Supplementary Table 3. The levofloxacin resistance rate was significantly lower in ST8-MRSA-IV than in all the other major MRSA types (q = 0.002 vs. ST8-MRSA-I and ST5-MRSA-II and q = 0.032 vs. CC1-MRSA-IV). The erythromycin resistance rate was also significantly lower in ST8-MRSA-IV than in ST8-MRSA-I. In contrast, the clindamycin resistance rate of ST5-MRSA-II was significantly higher than that of all other major MRSA types (q < 0.001 for all comparisons). CLSI and EUCAST guidelines differ in their protocols for determining minocycline resistance rates. All strains were sensitive to minocycline per the CLSI guidelines; however, when tested according to the EUCAST guidelines, a difference in minocycline resistance rates was observed among the major MRSA types. The minocycline resistance rate was significantly higher in ST8-MRSA-I and ST5-MRSA-II than in ST8-MRSA- IV and CC1-MRSA-IV. There were also differences in the MICs of beta-lactams, for which the CLSI or EUCAST did not set breakpoints for MRSA. The MICs of cefazolin, imipenem, and meropenem were lower for ST8-MRSA-IV and CC1-MRSA-IV than for ST8-MRSA-I and ST5- MRSA-II (Supplementary Fig. 1C-F). The MICs of imipenem against most strains belonging to the ST8-MRSA-IV and CC1-MRSA-IV were less than 0.5, in contrast to those of the ST8- MRSA-I and ST5-MRSA-II, which were higher than 16 (Supplementary Fig. 1E).

Molecular characteristics of the strains in the major MRSA types

Drug resistance and virulence genes differed among the major MRSA types. Although ST8- MRSA-IV and ST8-MRSA-I belonged to the same sequence type, the positivity rates for drug- resistance genes, such as aadD, ant(9)-Ia, erm(A), tet(M), and bleO, in ST8-MRSA-I were significantly higher than those in ST8-MRSA-IV (Fig. 3A). ST8-MRSA-I showed a similar trend with respect to its drug-resistance genes as that demonstrated by ST5-MRSA-II, except for aac(6′)-aph(2′′). However, the positivity rates for the virulence genes differed between ST8- MRSA-I and ST5-MRSA-II. The positivity rates for sec, seg, sei, sel, sem, seo, sep, seu, and tst were significantly higher in ST5-MRSA-II than in ST8-MRSA-I. In contrast, the positivity rate for splE was significantly lower in ST5-MRSA-II than that in ST8-MRSA-I (Fig. 3B). CC1- MRSA-IV has characteristic virulence gene features. It harbors virulence genes such as sea, seh, sek, and seq, which are absent in other major MRSA types.

• Download figure
• Open in new tab

Fig. 3. The positivity rates for drug-resistance and virulence genes in the major MRSA types

Drug-resistance (A) and virulence (B) genes were detected after whole-genome sequencing using ResFinder and virulence finder, respectively.

In ST8-MRSA-IV, the positivity rates for drug-resistance and virulence genes, such as aac(6′)- aph(2′′), aadD, ant(9)-Ia, erm(A), bleO, sec, sel, sep, tst, and splE, were around 50% (Fig. 3). Phylogenetic analysis based on core genome MLST revealed that ST8-MRSA-IV was divided into several clusters (Supplementary Fig. 2). Based on the results of the virulence genes sec and tst and the spa type,⁵ 14 and 4 strains were classified as CA-MRSA/J and t5071-ST8-MRSA-IV, respectively. There were significant differences between CA-MRSA/J and t5071-ST8-MRSA-IV gene expression (Supplementary Table 4). The positive rates for aac(6′)-aph(2′′), aadD, bleO, sec, sel, and tst were significantly higher in CA-MRSA/J than in t5071-ST8-MRSA-IV (p < 0.05), and those for ant(9)-Ia, erm(A), splE, and sep were significantly lower in CA-MRSA/J than in t5071-ST8-MRSA-IV (p < 0.05). Based on antimicrobial susceptibility testing, CA- MRSA/J was more sensitive to levofloxacin, erythromycin, clindamycin, and minocycline than was t5071-ST8-MRSA-IV (p < 0.05) (Supplementary Table 4).

Relationship between the strains detected in Nagasaki and those circulating in Japan

Phylogenetic tree analysis based on MLST, cgMLST, and S. aureus accessory sequences was performed to investigate the relationship between the strains detected in this study and those from the previous nationwide surveillance.⁵ Based on the phylogenetic tree analysis, the strains were divided into three major clusters, ST8-MRSA-IV and ST8-MRSA-I, CC1-MRSA-IV, and ST5-MRSA-II (Supplementary Fig. 3). In the ST8-MRSA-IV and ST8-MRSA-I clusters (Fig. 4A), most ST8-MRSA-I strains detected in Nagasaki and the nationwide surveillance were classified into subcluster 3, whereas ST8-MRSA-IV was divided into ten subgroups. However, in the ST8-MRSA-IV group, all CA-MRSA/J strains detected in Nagasaki and nationwide were classified into subcluster 1. All t5071-ST8-MRSA-IV strains detected in Nagasaki and nationwide were classified into subcluster 5. The ST5-MRSA-II strains showed the same trend as that of the ST8-MRSA-IV strains. The ST5-MRSA-II strains detected in Nagasaki were divided into five subclusters (Fig. 4C). In contrast to ST8-MRSA-IV and ST5-MRSA-II, most CC1- MRSA-IV strains detected in Nagasaki and nationwide surveillance were classified into the same sub-cluster 12 (Fig. 4B).

• Download figure
• Open in new tab

Fig. 4. Phylogenetic analysis of MRSA strains detected in Nagasaki and those circulating in Japan

Phylogenetic tree analysis was performed based on MLST, core genome MLST (cgMLST), and S. aureus accessory sequences to investigate the relationship between the strains detected in this study and those from the previous nationwide surveillance. Based on the phylogenetic tree analysis of all strains (Supplementary Fig. 3), the strains were divided into three major clusters: ST8-MRSA-IV and ST8-MRSA-I (A), CC1-MRSA-IV (B), and ST5-MRSA-II (C). cgMLST was performed using the Ridom SeqSphere+ v.9.0.10 (Ridom GmbH, Münster, Germany). A UPGMA tree was created based on MLST, cgMLST, and S. aureus accessory genes. Samples with more than 10% missing values among the data used for distance calculation were excluded. During UPGMA of the strains detected during the previous nationwide surveillance, the strains detected at Nagasaki University Hospital were excluded to avoid duplication.